Summary of Onxeo’s Liquidity Contract With Kepler Cheuvreux
01/07/2022 - 11:45 AM
PARIS --(BUSINESS WIRE)--
Regulatory News :
Under the liquidity contract entered into between ONXEO (Paris:ALONX) (NASDAQ OMX:ALONX) and Kepler Cheuvreux , the following resources appeared on the liquidity account on December 31st 2021 :
- 429,850 shares
- € 36,891.92
- Number of executions on buy side on semester: 256
- Number of executions on sell side on semester: 155
- Traded volume on buy side on semester: 357,510 shares for € 179,383.26
- Traded volume on sell side on semester: 221,580 shares for € 115,071.34
As a reminder:
• the following resources appeared on the last half year statement on 30 June 2021 on the liquidity account:
- 293,920 shares
- € 101,406.22
- Number of executions on buy side on semester: 122
- Number of executions on sell side on semester: 118
- Traded volume on buy side on semester: 225,004 shares for € 157,757.98
- Traded volume on sell side on semester: 203,522 shares for € 148,483.15
• the following resources appeared on the liquidity account when the activity started:
- 87,612 shares
- € 196,423.24
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.
About Onxeo
Onxeo ONXEO ) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the soughtafter field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.
AsiDNA™ , the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNAdamaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is evaluating the safety and efficacy of AsiDNA™ at a dose of 600 mg in combination with the reference chemotherapy, carboplatin -/+ paclitaxel, in advanced metastatic tumors. Preliminary results from both cohorts showed good tolerability, stabilization of the disease and an increase in treatment duration compared to previous treatments. The ongoing REVOCAN phase 1b/2 study evaluates the effect of AsiDNA™ on the acquired resistance to PARP inhibitor niraparib in relapsed ovarian cancer (sponsored by Gustave Roussy ). A phase 1b/2 study, AsiDNA™ Children, will be initiated in 2021 to evaluate the association of AsiDNA™ with radiotherapy in children with relapsed high-grade glioma (sponsored by Institut Curie).
OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.
For more information, please visit www.onxeo.com
Forward looking statements
This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent Company’s registration document or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group (www.onxeo.com ) and/or the AMF (www.amf-france.org ).
APPENDIX
Buy Side
Sell Side
Number of
Number of
Traded volume in EUR
Number of
Number of
Traded volume in EUR
Total
256
357,510
179,383.26
155
221,580
115,071.34
01/07/2021
1
1
0.64
1
1
0.64
07/07/2021
-
-
-
2
11
7.15
08/07/2021
7
7,733
4,717.13
1
1
0.63
09/07/2021
2
2,000
1,220.00
14
10,767
6,783.21
15/07/2021
2
5,001
3,100.62
1
1
0.63
16/07/2021
4
2,810
1,714.10
-
-
-
19/07/2021
7
6,457
3,938.77
-
-
-
20/07/2021
4
1,500
915.00
-
-
-
21/07/2021
2
1,000
600.00
-
-
-
22/07/2021
-
-
-
1
1
0.62
23/07/2021
1
1,306
783.60
4
5,000
3,050.00
27/07/2021
1
1
0.61
1
1
0.61
28/07/2021
10
9,694
5,816.40
-
-
-
29/07/2021
1
1
0.59
1
1
0.59
03/08/2021
1
1,000
580.00
-
-
-
06/08/2021
2
2,001
1,160.58
-
-
-
09/08/2021
5
1,701
986.58
-
-
-
10/08/2021
3
83
48.14
1
1
0.58
11/08/2021
1
216
125.28
-
-
-
16/08/2021
6
5,000
2,850.00
-
-
-
17/08/2021
-
-
-
4
10,000
5,900.00
18/08/2021
4
10,000
5,700.00
-
-
-
19/08/2021
-
-
-
3
5,000
2,900.00
20/08/2021
2
1,938
1,104.66
-
-
-
23/08/2021
1
1
0.59
2
2
1.18
24/08/2021
2
5,415
3,086.55
4
9,999
5,799.42
25/08/2021
1
1
0.58
2
5,151
3,090.60
26/08/2021
-
-
-
1
4,849
2,957.89
27/08/2021
7
6,046
3,567.14
1
1
0.60
30/08/2021
1
1,601
944.59
-
-
-
01/09/2021
2
5,000
2,900.00
-
-
-
03/09/2021
-
-
-
2
7,390
4,434.00
07/09/2021
1
5,000
2,900.00
7
3,137
1,850.83
08/09/2021
-
-
-
4
1,863
1,099.17
09/09/2021
-
-
-
2
523
313.80
10/09/2021
5
5,000
2,950.00
1
2,087
1,252.20
14/09/2021
5
5,000
2,900.00
-
-
-
17/09/2021
2
5,000
2,850.00
1
790
458.20
20/09/2021
2
5,000
2,800.00
3
136
77.52
22/09/2021
3
10,000
5,500.00
-
-
-
30/09/2021
1
1
0.56
1
1
0.56
01/10/2021
6
4,613
2,491.02
-
-
-
04/10/2021
4
2,387
1,288.98
2
4,864
2,675.20
05/10/2021
6
8,000
4,240.00
5
2,746
1,482.84
06/10/2021
3
4,945
2,571.40
-
-
-
07/10/2021
2
5,055
2,578.05
1
1
0.52
08/10/2021
-
-
-
3
901
468.52
12/10/2021
4
10,000
4,900.00
2
3,196
1,629.96
13/10/2021
3
5,000
2,450.00
10
14,536
7,558.72
14/10/2021
3
4,247
2,165.97
1
1,391
737.23
15/10/2021
4
5,753
2,991.56
-
-
-
21/10/2021
3
2,894
1,447.00
-
-
-
22/10/2021
3
2,106
1,053.00
-
-
-
26/10/2021
6
5,000
2,500.00
-
-
-
27/10/2021
-
-
-
1
33
16.83
28/10/2021
2
5,000
2,500.00
2
477
243.27
29/10/2021
1
1
0.50
1
1
0.50
03/11/2021
4
5,000
2,500.00
1
1,719
876.69
04/11/2021
2
2,918
1,429.82
-
-
-
05/11/2021
2
2,082
1,020.18
-
-
-
11/11/2021
3
5,000
2,400.00
-
-
-
12/11/2021
3
10,000
4,700.00
1
5,000
2,400.00
16/11/2021
13
18,732
8,429.40
-
-
-
17/11/2021
4
6,268
2,632.56
-
-
-
23/11/2021
1
1
0.43
1
1
0.43
24/11/2021
3
7,055
2,892.55
-
-
-
26/11/2021
3
5,000
2,050.00
2
1,778
764.54
29/11/2021
1
2,945
1,178.00
7
3,222
1,385.46
30/11/2021
1
2,412
964.80
-
-
-
01/12/2021
-
-
-
5
5,000
2,100.00
08/12/2021
7
8,611
3,444.40
-
-
-
09/12/2021
6
3,000
1,260.00
8
20,000
8,800.00
10/12/2021
1
977
459.19
26
60,000
30,600.00
14/12/2021
7
20,000
9,800.00
-
-
-
15/12/2021
5
3,963
1,862.61
-
-
-
16/12/2021
11
16,037
7,377.02
-
-
-
20/12/2021
4
5,000
2,350.00
2
5,000
2,400.00
21/12/2021
8
25,000
11,000.00
-
-
-
22/12/2021
3
5,000
2,100.00
3
10,001
4,400.44
23/12/2021
7
9,211
3,960.73
2
9,465
4,164.60
24/12/2021
2
5,789
2,431.38
1
534
234.96
28/12/2021
2
5,000
2,100.00
1
3,686
1,584.98
29/12/2021
-
-
-
2
1,314
565.02
31/12/2021
4
5,000
2,100.00
-
-
-
View source version on businesswire.com : https://www.businesswire.com/news/home/20220107005219/en/
Onxeo
investors@onxeo.com
Relations Presse
onxeo@newcap.eu
Relations Investisseurs / Communication stratégique
Emmanuel Huynh
onxeo@newcap.eu
Investor Relations US
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Certified Adviser for Nasdaq
www.kapitalpartner.dk
info@kapitalpartner.dk
Source: ONXEO
